Pure Global
NCT06370000

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality

REMAIN1: Relapse Prevention With Maintenance Oral Azacitidine in Transplant Eligible Patients With Acute Myeloid Leukemia Not Proceeding to Transplant Due to Racial or Socioeconomic Disparities
Virginia Commonwealth University·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Myeloid Leukemia
Drug/Device/Intervention
Oral Azacitidine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Virginia Commonwealth University
Location
Richmond, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Jun 01, 2024
End date
Oct 31, 2028
Enrollment
12 participants
Primary outcome

Rate of completion of at least 4 cycles an oral maintenance strategy for transplant eligible AML patients in CR who are medically underserved or have a disadvantage in the CDC SDOH domains

Summary

Test feasibility of an oral maintenance strategy for transplant eligible AML patients in
 first CR who are medically underserved or have a disadvantage in the CDC SDOH domains

ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06370000
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06370000 through Pure Global AI's free database. This Phase 4 trial is sponsored by Virginia Commonwealth University and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.